Xiaoping Zhang

发表

Affinity-based ranking of ligands for DPP-4 from mixtures.

K. Chapman, G. Adam, J. Athanasopoulos, 2007, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2019, Bioorganic & medicinal chemistry letters.

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.

W. Greenlee, D. Tulshian, R. Hodgson, 2012, Bioorganic & medicinal chemistry letters.

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.

N. Thornberry, B. Leiting, G. Eiermann, 2007, Bioorganic & medicinal chemistry letters.

Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.

W. Greenlee, D. Tulshian, R. Hodgson, 2012, Bioorganic & medicinal chemistry letters.

A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Bei B. Zhang, 2009, Bioorganic & medicinal chemistry letters.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Bei B. Zhang, 2009, Bioorganic & medicinal chemistry letters.

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.

A. Stamford, R. Hodgson, E. Parker, 2014, European journal of pharmacology.

Discovery of novel orally active ureido NPY Y5 receptor antagonists.

W. Greenlee, A. Stamford, C. Farley, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

J. Berger, Gaochao Zhou, Sanjeev Kumar, 2009, Journal of medicinal chemistry.

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

A. Woods, D. Zaller, N. Thornberry, 2005, Diabetes.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Kathy Lyons, Ping Chen, Dennis Feng, 2014, Journal of medicinal chemistry.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.

T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.

W. Greenlee, D. Tulshian, D. Burnett, 2010, Bioorganic & medicinal chemistry letters.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Sanjeev Kumar, 2009, Bioorganic & medicinal chemistry letters.

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

G. Scapin, J. Berger, N. Thornberry, 2017, Endocrinology, diabetes & metabolism.

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.

Margaret S. Wu, Q. Dang, D. Mackenna, 2017, Journal of medicinal chemistry.

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

Marc Poirier, Michael W. Miller, Christian Mirescu, 2017, Journal of medicinal chemistry.

Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design.

G. Scapin, Suresh B. Singh, N. Thornberry, 2008, Bioorganic & medicinal chemistry letters.

Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors.

R. Sheridan, G. Scapin, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

W. Greenlee, D. Tulshian, R. Hodgson, 2012, Bioorganic & medicinal chemistry letters.

The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.

W. Greenlee, D. Tulshian, R. Hodgson, 2012, Bioorganic & medicinal chemistry letters.

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

Lynn A. Hyde, J. Uslaner, Sean M. Smith, 2011, Neuropharmacology.

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.

A. Stamford, R. Hodgson, E. Parker, 2014, European journal of pharmacology.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.